DelveInsight’s, “Overactive Bladder Pipeline Insights 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Overactive Bladder pipeline landscape. It covers the Overactive Bladder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Overactive Bladder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Overactive Bladder Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Overactive Bladder Pipeline Outlook Report
Key Takeaways from the Overactive Bladder Pipeline Report
- In January 2025, Imbrium Therapeutics L.P. (“Imbrium”), a subsidiary of Purdue Pharma L.P. (“Purdue”), announced results from a Phase Ib clinical signal detection study evaluating the safety and efficacy of the novel investigational treatmentsunobinop in patients with overactive bladder syndrome.
- DelveInsight’s Overactive Bladder pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Overactive Bladder treatment.
- The leading Overactive Bladder Companies such as Dong-A ST Co., Ltd., AbbVie/Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics and others.
- Promising Overactive Bladder Pipeline Therapies such as GSK1358820, YM178, Fesoterodine 8 mg, Vibegron, Tolterodine ER, Solifenacin Succinate, Oxybutynin chloride OROS, VESIcare®, Fesoterodine, and others.
Discover how the Overactive Bladder treatment paradigm is evolving. Access DelveInsight’s in-depth Overactive Bladder Pipeline Analysis for a closer look at promising breakthroughs @ Overactive Bladder Clinical Trials and Studies
Overactive Bladder Emerging Drugs Profile
- Neuronox: AbbVie/Medytox
Neuronox, an acetylcholine inhibitor is being developed by Medy-Tox for the treatment of the Overactive Bladder. The active ingredients involve Clostridium botulinum toxin type A. It is currently in the phase III stage of development. In September 2020, US drugmaker Allergan entered into a license agreement with South Korea’s Medytox under the terms of which, on closing, Allergan would pay Medytox an upfront of USD 65 million and Medytox would grant Allergan exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialise certain neurotoxin product candidates currently in development, including a potential liquid-injectable product. In May 2020, AbbVie announced that it had finished its acquisition of Allergan plc following receipt of regulatory approval from all government authorities needed by the transaction agreement and approval by the Irish High Court.
- URO-902: Urovant Sciences
Urovant Sciences is developing URO-902 for the treatment of the Overactive Bladder. URO-902 has the potential to be the first gene therapy for OAB patients. This innovative treatment has the capability to tackle an unmet need for patients who have failed oral pharmacologic therapies and are concerned with potential urinary retention or surgical interventions pertinent to existing third-line OAB treatments. It is currently in the phase II stage of development.
The Overactive Bladder Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.
- Overactive Bladder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.
Get a detailed analysis of the latest innovations in the Overactive Bladder pipeline. Explore DelveInsight’s expert-driven report today! @ Overactive Bladder Unmet Needs
Overactive Bladder Companies
Dong-A ST Co., Ltd., AbbVie/Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics and others.
Overactive Bladder Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Overactive Bladder Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Download DelveInsight’s latest report to gain strategic insights into upcoming Overactive Bladder Therapies and key Developments @ Overactive Bladder Market Drivers and Barriers, and Future Perspectives
Scope of the Overactive Bladder Pipeline Report
- Coverage- Global
- Overactive Bladder Companies- Dong-A ST Co., Ltd., AbbVie/Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics and others.
- Overactive Bladder Pipeline Therapies- GSK1358820, YM178, Fesoterodine 8 mg, Vibegron, Tolterodine ER, Solifenacin Succinate, Oxybutynin chloride OROS, VESIcare®, Fesoterodine, and others.
- Overactive Bladder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Overactive Bladder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Overactive Bladder drug development? Find out in DelveInsight’s exclusive pipeline report—access it now! @ Overactive Bladder Emerging Drugs and Major Companies
Table of Contents
- Introduction
- Executive Summary
- Overactive Bladder: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Overactive Bladder– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Neuronox: AbbVie/Medytox
- Mid Stage Products (Phase II)
- URO-902: Sumitovant Biopharma
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Inactive Products
- Overactive Bladder Key Companies
- Overactive Bladder Key Products
- Overactive Bladder- Unmet Needs
- Overactive Bladder- Market Drivers and Barriers
- Overactive Bladder- Future Perspectives and Conclusion
- Overactive Bladder Analyst Views
- Overactive Bladder Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight
